Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion type Assertion NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_head.
- NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion description "[In this article entitled How many JAK inhibitors for myelofibrosis we discuss JAK2 as a target, review briefly the benefits to patients with MF of JAK inhibition and highlight some of the differences between the number of JAK inhibitors currently being evaluated.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_provenance.
- NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion evidence source_evidence_literature NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_provenance.
- NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion SIO_000772 25189729 NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_provenance.
- NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion wasDerivedFrom befree-2016 NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_provenance.
- NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_assertion wasGeneratedBy ECO_0000203 NP1217008.RAvf6Ex6sdB-5TIihpSu3mtLFzbcYiU7P0pI5NKPEEGeE130_provenance.